Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis

Author:

Rickard EmilyORCID,Carmel Emma,Ozieranski PiotrORCID

Abstract

ObjectivesTo examine the characteristics of pharmaceutical payments to healthcare and patient organisations in the four UK countries. Compare companies spending the most; types of organisations receiving payments and types of payments in the four countries. Measure the extent to which companies target payments at the same recipients in each country and whether it differs depending on the type of recipient.DesignCross-sectional comparative and social network analysis.SettingEngland, Scotland, Wales, Northern Ireland.Participants100 donors (pharmaceutical companies) reporting payments to 4229 recipients (healthcare organisations and patient organisations) in 2015.Main outcome measuresFor each country: payment totals and distribution; average number of common recipients between companies; share of payments to organisations fulfilling different roles in the health ecosystem and payments for different activities.ResultsCompanies prioritised different types of recipient and different types of activity in each country. There were significant differences in the distribution of payments across the four countries, even for similar types of recipients. Recipients in England and Wales received smaller individual payments than in Scotland and Northern Ireland. Overall, targeting shared recipients occurred most frequently in England, but was also common in certain pockets of each country’s health ecosystem. We found evidence of reporting errors in Disclosure UK.ConclusionsOur findings suggest a strategic approach to payments tailored to countries’ policy and decision-making context, indicating there may be specific vulnerabilities to financial conflicts of interest at subnational level. Payment differences between countries may be occurring in other countries, particularly those with decentralised health systems and/or high levels of independence across its decision-making authorities. We call for a single database containing all recipient types, full location details and published with associated descriptive and network statistics.

Funder

Vetenskapsrådet

Swedish Research Council for Health, Working Life and Welfare

Economic and Social Research Council

University of Bath

Publisher

BMJ

Subject

General Medicine

Reference94 articles.

1. Pharmaceutical company spending on research and development and promotion in canada, 2013-2016: a cohort analysis;Lexchin;J Pharm Policy Pract,2018

2. AHIP . New study: in the midst of COVID-19 crisis, 7 out of 10 big pharma companies spent more on sales and marketing than R&D. 2021. Available: https://www.ahip.org/news/articles/new-study-in-the-midst-of-covid-19-crisis-7-out-of-10-big-pharma-companies-spent-more-on-sales-and-marketing-than-r-d

3. Swanson A . Big pharmaceutical companies are spending far more on marketing than research. In: The Washington post. 2015.

4. Mulinari S , Ozieranski P . Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the association of the british pharmaceutical industry’s disclosure UK database, 2015 and 2016 cohorts. BMJ Open 2018;8:e023094. doi:10.1136/bmjopen-2018-023094

5. Rodwin MA . Conflict of interest in the pharmaceutical sector: A guide for public management. DePaul J Health Care L 2019;21.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3